AU2012305807A8 - Dengue-virus serotype neutralizing antibodies - Google Patents

Dengue-virus serotype neutralizing antibodies

Info

Publication number
AU2012305807A8
AU2012305807A8 AU2012305807A AU2012305807A AU2012305807A8 AU 2012305807 A8 AU2012305807 A8 AU 2012305807A8 AU 2012305807 A AU2012305807 A AU 2012305807A AU 2012305807 A AU2012305807 A AU 2012305807A AU 2012305807 A8 AU2012305807 A8 AU 2012305807A8
Authority
AU
Australia
Prior art keywords
dengue
neutralizing antibodies
virus serotype
virus
serotype neutralizing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2012305807A
Other versions
AU2012305807B2 (en
AU2012305807A1 (en
Inventor
Atchareeya A-nuegoonpipat
Surapee Anantapreecha
Panadda Dhepakson
Kazuyoshi Ikuta
Motoki Kuhara
Yoshinobu Okuno
Prawatsilpa Pattarin
Apichai Prachasuphap
Pongrama Ramasoota
Tadahiro Sasaki
Pathom Sawanpanyalert
Chayanee Setthapramote
Aree Thattiyaphong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical and Biological Laboratories Co Ltd
Osaka University NUC
Department of Medical Sciences (DMSc)
Mahidol University
Original Assignee
Department OF MEDICAL SCIENCES DMSC
Medical and Biological Laboratories Co Ltd
Research Foundation for Microbial Diseases of Osaka University BIKEN
Osaka University NUC
Mahidol University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Department OF MEDICAL SCIENCES DMSC, Medical and Biological Laboratories Co Ltd, Research Foundation for Microbial Diseases of Osaka University BIKEN, Osaka University NUC, Mahidol University filed Critical Department OF MEDICAL SCIENCES DMSC
Publication of AU2012305807A1 publication Critical patent/AU2012305807A1/en
Publication of AU2012305807A8 publication Critical patent/AU2012305807A8/en
Application granted granted Critical
Publication of AU2012305807B2 publication Critical patent/AU2012305807B2/en
Assigned to OSAKA UNIVERSITY, MAHIDOL UNIVERSITY, MEDICAL AND BIOLOGICAL LABORATORIES CO., LTD, Department of Medical Sciences (DMSc) reassignment OSAKA UNIVERSITY Request for Assignment Assignors: Department of Medical Sciences (DMSc), MAHIDOL UNIVERSITY, MEDICAL AND BIOLOGICAL LABORATORIES CO., LTD, OSAKA UNIVERSITY, THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Materials and methods are provided for treating dengue infections. Human monoclonal antibodies against all serotypes of dengue virus are also provided. Methods of using human monoclonal antibodies to neutralize all dengue-virus serotypes are provided using patients' peripheral blood lymphocytes.
AU2012305807A 2011-09-09 2012-09-07 Dengue-virus serotype neutralizing antibodies Active AU2012305807B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161532671P 2011-09-09 2011-09-09
US201161532605P 2011-09-09 2011-09-09
US61/532,671 2011-09-09
US61/532,605 2011-09-09
PCT/JP2012/005699 WO2013035345A2 (en) 2011-09-09 2012-09-07 Dengue-virus serotype neutralizing antibodies

Publications (3)

Publication Number Publication Date
AU2012305807A1 AU2012305807A1 (en) 2014-02-20
AU2012305807A8 true AU2012305807A8 (en) 2014-03-13
AU2012305807B2 AU2012305807B2 (en) 2015-08-20

Family

ID=47116163

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012305807A Active AU2012305807B2 (en) 2011-09-09 2012-09-07 Dengue-virus serotype neutralizing antibodies

Country Status (4)

Country Link
AU (1) AU2012305807B2 (en)
MY (1) MY170725A (en)
SG (1) SG11201400100SA (en)
WO (1) WO2013035345A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2938590C (en) 2014-02-11 2023-10-17 Visterra, Inc. Antibody molecules to dengue virus and uses thereof
CN105004860B (en) * 2015-07-24 2016-09-21 鲁东大学 Florfenicol quick detection kit and preparation, using method
CN105137068B (en) * 2015-07-24 2017-03-01 鲁东大学 Florfenicol Site Detection reagent paper and its preparation, using method
TWI763660B (en) 2016-03-25 2022-05-11 美商威特拉公司 Formulations of antibody molecules to dengue virus
CN109929033B (en) * 2019-03-15 2020-06-02 中国人民解放军军事科学院军事医学研究院 Human antibody specifically binding to four serotype dengue viruses

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5169939A (en) 1985-05-21 1992-12-08 Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College Chimeric antibodies
GB8800077D0 (en) 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
US6042828A (en) 1992-09-07 2000-03-28 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
PL174721B1 (en) 1992-11-13 1998-09-30 Idec Pharma Corp Monoclonal antibody anty-cd2
DE4337197C1 (en) 1993-10-30 1994-08-25 Biotest Pharma Gmbh Process for the selective preparation of hybridoma cell lines which produce monoclonal antibodies with high cytotoxicity against human CD16 antigen, and the preparation of bispecific monoclonal antibodies using such monoclonal antibodies and the CD30-HRS-3 antibody for therapy of human tumours
JP2002514919A (en) 1997-04-04 2002-05-21 バイオサイト ダイアグノスティックス，インコーポレイテッド Multivalent and polyclonal libraries
EP1597280B2 (en) * 2003-02-26 2016-08-24 Institute for Research in Biomedicine Monoclonal antibody production by ebv transformation of b cells
EP2009094B1 (en) * 2006-04-13 2010-06-09 Medical and Biological Laboratories Co., Ltd. Fusion partner cells
US8337854B2 (en) * 2007-04-04 2012-12-25 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Monoclonal antibodies against dengue and other viruses with deletion in Fc region
WO2010043977A2 (en) * 2008-10-13 2010-04-22 Institute For Research In Biomedicine Dengue virus neutralizing antibodies and uses thereof
JP5780762B2 (en) * 2008-12-25 2015-09-16 国立大学法人大阪大学 Anti-human influenza virus / human antibody
SG173482A1 (en) * 2009-02-10 2011-09-29 Univ Nanyang Tech Antibodies for diagnosis and treatment of flaviviral infections

Also Published As

Publication number Publication date
AU2012305807B2 (en) 2015-08-20
WO2013035345A2 (en) 2013-03-14
AU2012305807A1 (en) 2014-02-20
WO2013035345A3 (en) 2013-09-06
SG11201400100SA (en) 2014-06-27
MY170725A (en) 2019-08-27

Similar Documents

Publication Publication Date Title
PH12017501075A1 (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
CY1123739T1 (en) ANTI-CD38 ANTIBODIES
PH12016500859B1 (en) Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
EA201490004A1 (en) BIFIDOBACTERIUM LACTIS BL-04 APPLICATION FOR TREATMENT OF RESPIRATORY DISEASES
EA201300016A1 (en) HUMAN ANTIBODY CONJUGATES AGAINST TISSUE FACTOR WITH DRUGS
EA032929B1 (en) Human immunodeficiency virus neutralizing antibody and methods of use thereof
UA109633C2 (en) HUMAN ANTIBODY AGAINST TISSUE FACTOR
MX2012001882A (en) Antibodies against human respiratory syncytial virus (rsv) and methods of use.
MX350200B (en) Human antibodies and antibody-drug conjugates against cd74.
MX2015009416A (en) Human antibodies to respiratory syncytial virus f protein and methods of use thereof.
EP2558493A4 (en) Antibodies for the treatment of clostridium difficile-associated infection and disease
UA112288C2 (en) Antibody forvulation and therapeutic regimens
DE602007013618D1 (en) ANTIBODIES TO THE HUMAN CYTOMEGALIE VIRUS (HCMV)
MX347734B (en) S100a4 antibodies and therapeutic uses thereof.
BR112013032456A2 (en) anti-cxcr4 antibody with effector functions and its use for cancer treatment
AU2012305807A8 (en) Dengue-virus serotype neutralizing antibodies
EA201300132A1 (en) PHARMACEUTICAL COMPOSITION AND METHODS OF TREATMENT AND PREVENTION OF DISEASES CAUSED BY HIV OR ASSOCIATED WITH HIV
EA201390417A1 (en) ANTI-DIABETIC SOLID PHARMACEUTICAL COMPOSITIONS
MX2013010367A (en) Compositions and methods for the therapy and diagnosis of influenza.
MX2013009529A (en) Treatment of fistulizing crohn's disease.
WO2012119989A3 (en) Antibodies against cadmi for the diagnosis and treatment of cancer
WO2012009640A3 (en) B cell depletion for central nervous system injuries and methods and uses thereof
WO2012149525A3 (en) Ureaplasma vaccine and antibody for prevention and treatment of human, animal and cell culture infection
TH141036A (en) Antibodies neutralize specific activity against the serotope of the dengue virus. (DENGUE-VIRUS SEROTYPE NEUTRALIZING ANTIBODIES)
EA201992775A3 (en) HUMAN ANTIBODIES CONJUGATES AGAINST TISSUE FACTOR WITH MEDICINES

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 28 , NO 7 , PAGE(S) 975 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME OSAKA UNIVERSITY; MAHIDOL UNIVERSITY; DEPARTMENT OF MEDICAL SCIENCES (DMSC); THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY; MEDICAL AND BIOLOGICAL LABORATORIES CO., LTD, APPLICATION NO. 2012305807, UNDER INID (72), ADD CO-INVENTOR PATTARIN, PRAWATSILPA

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: OSAKA UNIVERSITY

Free format text: FORMER OWNER(S): MAHIDOL UNIVERSITY; OSAKA UNIVERSITY; THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY; DEPARTMENT OF MEDICAL SCIENCES (DMSC); MEDICAL AND BIOLOGICAL LABORATORIES CO., LTD

Owner name: MAHIDOL UNIVERSITY

Free format text: FORMER OWNER(S): MAHIDOL UNIVERSITY; OSAKA UNIVERSITY; THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY; DEPARTMENT OF MEDICAL SCIENCES (DMSC); MEDICAL AND BIOLOGICAL LABORATORIES CO., LTD

Owner name: MEDICAL AND BIOLOGICAL LABORATORIES CO., LTD

Free format text: FORMER OWNER(S): MAHIDOL UNIVERSITY; OSAKA UNIVERSITY; THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY; DEPARTMENT OF MEDICAL SCIENCES (DMSC); MEDICAL AND BIOLOGICAL LABORATORIES CO., LTD

Owner name: DEPARTMENT OF MEDICAL SCIENCES (DMSC)

Free format text: FORMER OWNER(S): MAHIDOL UNIVERSITY; OSAKA UNIVERSITY; THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY; DEPARTMENT OF MEDICAL SCIENCES (DMSC); MEDICAL AND BIOLOGICAL LABORATORIES CO., LTD